Clinical trials: Antibody Mediated
COVID-19
A Longitudinal Study of COVID-19 Sequelae and Immunity
Background: COVID-19 is a disease caused by the SARS-CoV-2 virus. It infects the respiratory tract. Some people who get COVID-19 have only mild symptoms.
- Trial name
- NCT04411147
- Where
- United States
- Volunteers
- 583 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Cardiac Allograft Vasculopathy, Antibody Mediated Rejection
Endothelial Injury and Development of Coronary Intimal Thickening After Heart Transplantation
Coronary allograft vasculopathy (CAV) is the leading cause of late graft failure and second leading cause of late mortality after heart transplantation.
- Trial name
- NCT01848301
- Testing
- Optical Coherence Tomography, Acetylcholine, Brachial Artery Flow Mediated Dilation
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Gladwin, Mark, MD
Immunity; Defect Due to Antibody or Cell Mediated Immune Defect
Cytokine Production and Immunity to Varicella Zoster Virus (VZV) in Elderly Recipients of Zoster Vaccine
After immunization, particularly in older persons, some people are protected from disease by a vaccine and others are not. The investigators believe that this variable response may be due to overproduction of molecules that…
- Trial name
- NCT01288014
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Columbia University
Hepatitis C
Prevention of Graft Reinfection After Liver Transplantation With Anti HCV Monoclonal Antibodies Identified in Chronically Infected Patients or in Patients With Resolved Hepatitis C
End stage HCV-related cirrhosis has become a major indication for liver transplantation (LT). Unfortunately, recurrence of HCV infection on the liver graft occurs in almost all patients following transplantation and causes a…
- Trial name
- NCT00638144
- Where
- 3 sites in France
- Volunteers
- 300 people
- Sponsor
- University Hospital, Strasbourg, France
Lung Transplantation
Syk Inhibition in MItigating Lung Allograft Rejection (SIMILAR): A Trial to Evaluate the Safety and Tolerability of Fostamatinib in Lung Transplant Patients With Donor-Specific Antibodies
Background: People who have lung transplants often survive 6 or 7 years. But some people develop donor-specific antibodies (DSA) after their transplants; antibodies are proteins that attack foreign invaders in the body.
- Trial name
- NCT06948097
- Testing
- fostamatinib
- Where
- 4 sites in United States
- Volunteers
- 30 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Allografts, Rejection; Transplant, Kidney
A Study to Evaluate the Safety and Efficacy of Dual Costimulation Blockade With VIB4920 and Belatacept for Prophylaxis of Allograft Rejection in Adults Receiving a Kidney Transplant
The purpose of this study is to evaluate the efficacy, safety and tolerability of dual costimulation blockade with VIB4920 in combination of belatacept in adult male or female recipients of a renal allograft from a deceased…
- Conditions
- Allografts, Rejection; Transplant, Kidney, Transplant Rejection, Kidney Transplantation
- Trial name
- NCT04046549
- Testing
- Belatacept, VIB4920, Thymoglobulin
- Where
- 4 sites in United States
- Volunteers
- 25 people
- Sponsor
- Amgen
Kidney Transplant Rejection
An Long-term Follow-up Trial of Kidney Tx Patients Treated With Imlifidase or PE After an AMR
The aim of this trial is to collect data and provide a better understanding of the long-term outcome of imlifidase treatment on active or chronic active antibody-mediated rejection (AMR) in kidney transplant recipients.
- Trial name
- NCT04711850
- Testing
- Imlifidase
- Where
- 7 sites in Austria, France and 1 more
- Volunteers
- 18 people
- Sponsor
- Hansa Biopharma AB
Behcet's Disease, Idiopathic Inflammatory Myopathies
Drug Rediscovery for Rare Immune Mediated Inflammatory Diseases
Research into novel therapies for rare, immune-mediated inflammatory diseases (IMIDs) is limited due to small patient populations.
- Conditions
- Behcet's Disease, Idiopathic Inflammatory Myopathies, IgG4-related Disease
- Trial name
- DRIMID (NCT06285539)
- Testing
- Filgotinib
- Where
- 6 sites in Netherlands
- Volunteers
- 60 people
- Sponsor
- UMC Utrecht
Warm Autoimmune Hemolytic Anemia
ALXN1830 in Patients With Warm Autoimmune Hemolytic Anemia
The main objective of the study is to evaluate the safety and efficacy of ALXN1830 compared to placebo in adult participants with warm autoimmune hemolytic anemia (WAIHA).
- Trial name
- NCT04256148
- Testing
- ALXN1830
- Where
- United States
- Sponsor
- Alexion Pharmaceuticals, Inc.
Lung Transplant Rejection, Antibody-mediated Rejection
Lung Transplant Plasmapheresis/Belatacept/Carfilzomib for Antibody Mediated Rejection and Desensitization
Antibody mediated rejection (AMR) post transplant contributes to poor long term outcomes after lung transplantation. Additionally, high antibodies detected pre transplant in candidates limit donor availability for lung…
- Trial name
- NCT03805178
- Testing
- Belatacept, Carfilzomib
- Sponsor
- Duke University
Transplant Rejection
BIVV020 (SAR445088) in Prevention and Treatment of Antibody-mediated Rejection (AMR)
Primary Objectives: Cohort A: To evaluate the efficacy of BIVV020 in prevention of AMR Cohort B: To evaluate the efficacy of BIVV020 in treatment of active AMR Secondary Objectives: To assess the overall efficacy of BIVV020 in…
- Trial name
- NCT05156710
- Testing
- BIVV020 (SAR445088), Intravenous immunoglobulin (IVIg), Rituximab or biosimilar
- Where
- 27 sites in United States, Canada and 5 more
- Volunteers
- 48 people
- Sponsor
- Sanofi
Eye Diseases
Immune Responses to Antigens in Non-infectious Eye Inflammatory Diseases
This study will collect blood samples from patients with non-infectious eye inflammatory diseases a spectrum of eye disorders that can produce sight-threatening vision loss.
- Trial name
- NCT00357071
- Where
- United States
- Volunteers
- 219 people
- Sponsor
- National Eye Institute (NEI)
Antibody-mediated Rejection in Kidney Transplant
Use of Extracorporeal Photopheresis in Kidney Transplantation: Effects on Antibody-Mediated Rejection
This study aims to describe, over a one-year period, the clinical, biological, and histological evolution of a cohort of kidney transplant recipients who developed antibody-mediated rejection and were treated with extracorporeal…
- Trial name
- PETRUM (NCT07663669)
- Where
- France
- Volunteers
- 31 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Kidney Transplantation
rATG Versus rATG Combined With Intravenous Immunoglobulin (IVIG) Induction Immunosuppression in HLA Incompatible Transplantation (INHIBIT)
This study aims to prove similar efficacy of PE/rATG (intervention) and PE/rATG/IVIG (centre standard of care) induction regimens to prevent biopsy proven antibody-mediated changes and TCMR as composite endpoint within 12 months…
- Trial name
- INHIBIT (NCT04302805)
- Testing
- Privigen, Thymoglobulin, Plasma Exchange
- Where
- Czechia
- Volunteers
- 17 people
- Sponsor
- Institute for Clinical and Experimental Medicine
ANCA Associated Vasculitis, CMV Infection
CMV Modulation of the Immune System in ANCA-associated Vasculitis
The purpose of this study is to determine whether Cytomegalovirus (CMV) reactivation in ANCA-associated vasculitis (AAV) patients can be effectively and safely reduced using an antiviral agent (valaciclovir) and whether this in…
- Trial name
- CANVAS (NCT01633476)
- Testing
- Valaciclovir
- Where
- United Kingdom
- Volunteers
- 38 people
- Sponsor
- Professor Lorraine Harper
IgG4 Related Disease, IgG4-RD
Elotuzumab in Immunoglobulin G4-Related Disease (IgG4-RD)
This is a two-part multi-center clinical trial in participants with active IgG4-RD. Part 1 (Cohort 1a and Cohort 1B) is an open-label, dose escalation phase to determine the safety of elotuzumab for investigation in IgG4-RD.
- Trial name
- NCT04918147
- Testing
- elotuzumab, methylprednisolone, diphenhydramine
- Where
- 3 sites in United States
- Volunteers
- 8 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Relapsed and Refractory Multiple Myeloma
Mezigdomide Plus Ixazomib and Dexamethasone for Relapsed and Refractory Multiple Myeloma
Multiple myeloma (MM) is the second most common hematologic malignancy with an estimated annual incidence of nearly 35,000 cases.
- Trial name
- NCT06050512
- Testing
- Mezigdomide, Ixazomib, Dexamethasone
- Sponsor
- Kathleen Dorritie
Transplant Glomerulopathy
Treatment of Chronic Antibody-mediated Rejection in Kidney Transplant With Acthar
This is an open label safety and feasibility trial using Acthar® in addition to the investigators center-specific standard therapy, which could include increase in maintenance immunosuppression, high dose IVIG (intravenous…
- Trial name
- TGActhar (NCT02546492)
- Testing
- Acthar gel
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- University of Maryland, Baltimore
IgM MGUS, Waldenstrom Macroglobulinemia
ACALA-R In Predominantly Demyelinating IgM Mediated Neuropathy
In this research study, is combining a new treatment acalabrutinib with a standard treatment, rituximab or other CD20 antibody, to determine whether this combination is safe and effective for participants with Immunoglobulin (Ig)…
- Conditions
- IgM MGUS, Waldenstrom Macroglobulinemia, Neuropathy;Peripheral
- Trial name
- NCT05065554
- Testing
- Acalabrutinib, Rituximab
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Shayna Sarosiek, MD
Rheumatoid Arthritis
Drug Concentration, Immunogenicity, and Efficacy Study in Patients With Rheumatoid Arthritis Currently Treated With Etanercept, Adalimumab, or Infliximab
The purpose of this study is to examine the relationship between anti-drug antibodies, serum drug concentrations, and clinical response for rheumatoid arthritis patients being treated with etanercept, adalimumab or infliximab.
- Trial name
- ANTIBODY-RA (NCT01981473)
- Testing
- no intervention
- Where
- 54 sites in United States, Argentina and 3 more
- Volunteers
- 605 people
- Sponsor
- Pfizer